An announcement from Moleculin Biotech (MBRX) is now available.
Moleculin Biotech, Inc. has launched an exciting Phase 2 study to evaluate the efficacy of WP1066 in combination with radiation therapy for adults with glioblastoma. This collaborative study could mark a significant step forward in the treatment of this aggressive brain cancer, potentially offering new hope to patients and intriguing possibilities for investors in the biotech sector.
Learn more about MBRX stock on TipRanks’ Stock Analysis page.
